Developing a pipeline of ground-breaking inhaled pharmaceutical products  

The initial focus of our product portfolio has been on pharmaceutical-grade cannabinoids for specific medical conditions

Senzer is a supplier of Unlicensed Medicines for patients with unmet medical needs through its regulated distribution network. We believe that patients should have access to innovative products and treatment options with confidence in their quality and safety.

Devices are CE marked and manufactured at a specialised facility located in the UK, and all manufacturing complies with strict GMP, ISO 13485, FDA’s CFR Title 21 Part 820 and the EU’s Medical Device Directive 93/42/EEC regulations.

Development Pipeline

Scroll across to see more data
Patient Information Phase I Phase II Phase III
Neurology
PK/PD & Safety
SZ101, SZ102, SZ103
Multiple Sclerosis
SZ103
Opioid Dependence
SZ103
Oncology
Chemotherapy Induced Peripheral
SZ103
Chemotherapy Induced Nausea & Vomiting
SZ101
Cancer Cachexia
SZ103
Completed Studies
Planned Studies, currently in study design phase with academic partners
SZ101
inhaled THC
SZ102
inhaled CBD
SZ103
inhaled THC:CBD

Project Twenty21

Together with other industry partners, Senzer has joined Europe’s first and largest national medical cannabis registry, called Project Twenty21, launched by Drug Science.

Project TWENTY21 aims to enroll 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis.TWENTY21 is a registry, not a clinical trial. The registry will be in first instance focusing predominantly on patients with the following conditions: Anxiety Disorder, Chronic Pain, Epilepsy, Multiple Sclerosis (MS), Post Traumatic Stress, Disorder (PTSD), Substance Use Disorder (as a harm reduction strategy), Tourette’s Syndrome.

For more information please visit: Drug Science Project Twenty21